Kepp O, et al. Consensus guidelines for the detection of immunogenic cell death. Oncoimmunology. 2014;3(9):e955691.
Article
PubMed
PubMed Central
Google Scholar
Vacchelli E, et al. Loss-of-function alleles of P2RX7 and TLR4 fail to affect the response to chemotherapy in non-small cell lung cancer. Oncoimmunology. 2012;1(3):271–8.
Article
PubMed
PubMed Central
Google Scholar
Ladoire S, et al. In situ immune response after neoadjuvant chemotherapy for breast cancer predicts survival. J Pathol. 2011;224(3):389–400.
Article
CAS
PubMed
Google Scholar
Angell H, Galon J. From the immune contexture to the Immunoscore: the role of prognostic and predictive immune markers in cancer. Curr Opin Immunol. 2013;25(2):261–7.
Article
CAS
PubMed
Google Scholar
Galon J, et al. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science. 2006;313(5795):1960–4.
Article
CAS
PubMed
Google Scholar
Peng RQ, et al. Expression of calreticulin is associated with infiltration of T-cells in stage IIIB colon cancer. World J Gastroenterol. 2010;16(19):2428–34.
Article
CAS
PubMed
PubMed Central
Google Scholar
Stoll G, et al. Immune-related gene signatures predict the outcome of neoadjuvant chemotherapy. Oncoimmunology. 2014;3(1):e27884.
Article
PubMed
PubMed Central
Google Scholar
Rabinovich GA, Gabrilovich D, Sotomayor EM. Immunosuppressive strategies that are mediated by tumor cells. Annu Rev Immunol. 2007;25:267–96.
Article
CAS
PubMed
PubMed Central
Google Scholar
Bernal-Estevez D, et al. Chemotherapy and radiation therapy elicits tumor specific T cell responses in a breast cancer patient. BMC Cancer. 2016;16:591.
Article
PubMed
PubMed Central
Google Scholar
Symmans WF, et al. Measurement of residual breast cancer burden to predict survival after neoadjuvant chemotherapy. J Clin Oncol. 2007;25(28):4414–22.
Article
PubMed
Google Scholar
Martinuzzi E, et al. Accelerated co-cultured dendritic cells (acDCs) enhance human antigen-specific T-cell responses. Blood. 2011;
Mailliard RB, et al. Alpha-type-1 polarized dendritic cells: a novel immunization tool with optimized CTL-inducing activity. Cancer Res. 2004;64(17):5934–7.
Article
CAS
PubMed
Google Scholar
Jonuleit H, et al. Pro-inflammatory cytokines and prostaglandins induce maturation of potent immunostimulatory dendritic cells under fetal calf serum-free conditions. Eur J Immunol. 1997;27(12):3135–42.
Article
CAS
PubMed
Google Scholar
Lipsitz SR, Kim K, Zhao L. Analysis of repeated categorical data using generalized estimating equations. Stat Med. 1994;13(11):1149–63.
Article
CAS
PubMed
Google Scholar
Whiteside TL. Induced regulatory T cells in inhibitory microenvironments created by cancer. Expert Opin Biol Ther. 2014;14(10):1411–25.
Article
CAS
PubMed
PubMed Central
Google Scholar
Hamilton MJ, et al. Macrophages are more potent immune suppressors ex vivo than immature myeloid-derived suppressor cells induced by metastatic murine mammary carcinomas. J Immunol. 2014;192(1):512–22.
Article
CAS
PubMed
Google Scholar
Markowitz J, et al. Myeloid-derived suppressor cells in breast cancer. Breast Cancer Res Treat. 2013;140(1):13–21.
Article
CAS
PubMed
PubMed Central
Google Scholar
Wolf AM, et al. Increase of regulatory T cells in the peripheral blood of cancer patients. Clin Cancer Res. 2003;9(2):606–12.
PubMed
Google Scholar
Marigo I, et al. Tumor-induced tolerance and immune suppression by myeloid derived suppressor cells. Immunol Rev. 2008;222:162–79.
Article
CAS
PubMed
Google Scholar
Della Bella S, et al. Altered maturation of peripheral blood dendritic cells in patients with breast cancer. Br J Cancer. 2003;89(8):1463–72.
Article
CAS
PubMed
Google Scholar
Limagne E, et al. Accumulation of MDSC and Th17 cells in patients with metastatic colorectal cancer predicts the efficacy of a FOLFOX-bevacizumab drug treatment regimen. Cancer Res. 2016;76(18):5241–52.
Article
CAS
PubMed
Google Scholar
Gottfried E, Kreutz M, Mackensen A. Tumor-induced modulation of dendritic cell function. Cytokine Growth Factor Rev. 2008;19(1):65–77.
Article
CAS
PubMed
Google Scholar
Finn OJ. Cancer immunology. N Engl J Med. 2008;358(25):2704–15.
Article
CAS
PubMed
Google Scholar
Krowka JF, et al. Expression of CD69 after in vitro stimulation: a rapid method for quantitating impaired lymphocyte responses in HIV-infected individuals. J Acquir Immune Defic Syndr Hum Retrovirol. 1996;11(1):95–104.
Article
CAS
PubMed
Google Scholar
Wieland E, Shipkova M. Lymphocyte surface molecules as immune activation biomarkers. Clin Biochem. 2016;49(4–5):347–54.
Article
CAS
PubMed
Google Scholar
Cochran JR, et al. Receptor clustering and transmembrane signaling in T cells. Trends Biochem Sci. 2001;26(5):304–10.
Article
CAS
PubMed
Google Scholar
Mackey MF, Barth RJ Jr, Noelle RJ. The role of CD40/CD154 interactions in the priming, differentiation, and effector function of helper and cytotoxic T cells. J Leukoc Biol. 1998;63(4):418–28.
Article
CAS
PubMed
Google Scholar
Van Gool SW, et al. CD80, CD86 and CD40 provide accessory signals in a multiple-step T-cell activation model. Immunol Rev. 1996;153:47–83.
Article
CAS
PubMed
Google Scholar
Mittal D, et al. New insights into cancer immunoediting and its three component phases--elimination, equilibrium and escape. Curr Opin Immunol. 2014;27:16–25.
Article
CAS
PubMed
PubMed Central
Google Scholar
Desmedt C, et al. Multifactorial approach to predicting resistance to anthracyclines. J Clin Oncol. 2011;29(12):1578–86.
Article
CAS
PubMed
Google Scholar
Zitvogel L, Tesniere A, Kroemer G. Cancer despite immunosurveillance: immunoselection and immunosubversion. Nat Rev Immunol. 2006;6(10):715–27.
Article
CAS
PubMed
Google Scholar
Datta J, et al. Progressive loss of anti-HER2 CD4+ T-helper type 1 response in breast tumorigenesis and the potential for immune restoration. Oncoimmunology. 2015;4(10):e1022301.
Article
PubMed
PubMed Central
Google Scholar
Ge Y, et al. Metronomic cyclophosphamide treatment in metastasized breast cancer patients: immunological effects and clinical outcome. Cancer Immunol Immunother. 2012;61(3):353–62.
Article
CAS
PubMed
Google Scholar
Verma C, et al. Abnormal T regulatory cells (Tregs: FOXP3+, CTLA-4+), myeloid-derived suppressor cells (MDSCs: monocytic, granulocytic) and polarised T helper cell profiles (Th1, Th2, Th17) in women with large and locally advanced breast cancers undergoing neoadjuvant chemotherapy (NAC) and surgery: failure of abolition of abnormal treg profile with treatment and correlation of treg levels with pathological response to NAC. J Transl Med. 2013;11:16.
Article
PubMed
PubMed Central
Google Scholar
Yu J, et al. Myeloid-derived suppressor cells suppress antitumor immune responses through IDO expression and correlate with lymph node metastasis in patients with breast cancer. J Immunol. 2013;190(7):3783–97.
Article
CAS
PubMed
Google Scholar
Diaz-Montero CM, et al. Increased circulating myeloid-derived suppressor cells correlate with clinical cancer stage, metastatic tumor burden, and doxorubicin-cyclophosphamide chemotherapy. Cancer Immunol Immunother. 2009;58(1):49–59.
Article
CAS
PubMed
Google Scholar
Lee JJ, et al. Type 1-polarized dendritic cells loaded with autologous tumor are a potent immunogen against chronic lymphocytic leukemia. J Leukoc Biol. 2008;84(1):319–25.
Article
CAS
PubMed
PubMed Central
Google Scholar
Verronese E, et al. Immune cell dysfunctions in breast cancer patients detected through whole blood multi-parametric flow cytometry assay. Oncoimmunology. 2016;5(3):e1100791.
Article
CAS
PubMed
Google Scholar
Shurin GV, et al. Chemotherapeutic agents in noncytotoxic concentrations increase antigen presentation by dendritic cells via an IL-12-dependent mechanism. J Immunol. 2009;183(1):137–44.
Article
CAS
PubMed
PubMed Central
Google Scholar
Shu U, et al. Activated T cells induce interleukin-12 production by monocytes via CD40-CD40 ligand interaction. Eur J Immunol. 1995;25(4):1125–8.
Article
CAS
PubMed
Google Scholar
Stuber E, Strober W, Neurath M. Blocking the CD40L-CD40 interaction in vivo specifically prevents the priming of T helper 1 cells through the inhibition of interleukin 12 secretion. J Exp Med. 1996;183(2):693–8.
Article
CAS
PubMed
Google Scholar
Alderson MR, et al. CD40 expression by human monocytes: regulation by cytokines and activation of monocytes by the ligand for CD40. J Exp Med. 1993;178(2):669–74.
Article
CAS
PubMed
Google Scholar
Campbell KA, et al. CD40 ligand is required for protective cell-mediated immunity to Leishmania major. Immunity. 1996;4(3):283–9.
Article
CAS
PubMed
Google Scholar
Caux C, et al. Activation of human dendritic cells through CD40 cross-linking. J Exp Med. 1994;180(4):1263–72.
Article
CAS
PubMed
Google Scholar
Cella M, et al. Ligation of CD40 on dendritic cells triggers production of high levels of interleukin-12 and enhances T cell stimulatory capacity: T-T help via APC activation. J Exp Med. 1996;184(2):747–52.
Article
CAS
PubMed
Google Scholar
Kelsall BL, et al. Interleukin-12 production by dendritic cells. The role of CD40-CD40L interactions in Th1 T-cell responses. Ann N Y Acad Sci. 1996;795:116–26.
Article
CAS
PubMed
Google Scholar
Kiener PA, et al. Stimulation of CD40 with purified soluble gp39 induces proinflammatory responses in human monocytes. J Immunol. 1995;155(10):4917–25.
CAS
PubMed
Google Scholar
Koch F, et al. High level IL-12 production by murine dendritic cells: upregulation via MHC class II and CD40 molecules and downregulation by IL-4 and IL-10. J Exp Med. 1996;184(2):741–6.
Article
CAS
PubMed
Google Scholar
Gu-Trantien C, et al. CD4(+) follicular helper T cell infiltration predicts breast cancer survival. J Clin Invest. 2013;123(7):2873–92.
Article
CAS
PubMed
PubMed Central
Google Scholar
Ladoire S, et al. Immunogenic cell death-related biomarkers: impact on the survival of breast cancer patients after adjuvant chemotherapy. Oncoimmunology. 2016;5(2):e1082706.
Article
PubMed
Google Scholar
Sistigu A, et al. Cancer cell-autonomous contribution of type I interferon signaling to the efficacy of chemotherapy. Nat Med. 2014;20(11):1301–9.
Article
CAS
PubMed
Google Scholar